Tropical Journal of Pharmaceutical Research

Review Article | OPEN ACCESS

Abnormally activated signaling pathways as potential therapeutic targets, and diagnostic biomarkers in the management of small-cell lung cancers – A review

Lihai Zhang, Longxia Dai, Jian Xiao, Bixiu He

Department of Elderly Respiratory, Xiangya Hospital, Central South University, Changsha 410008, China;

For correspondence:- Bixiu He Email: hebixiuhbx@163.com

Accepted: 1 December 2021 Published: 31 December 2021

Citation: Zhang L, Dai L, Xiao J, He B. Abnormally activated signaling pathways as potential therapeutic targets, and diagnostic biomarkers in the management of small-cell lung cancers – A review. Trop J Pharm Res 2021; 20(12):2675-2679 doi: 10.4314/tjpr.v20i12.30

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Small-cell lung cancer (SCLC) has relatively aggressive spread characteristics and a poor prognosis. Current treatment methods include surgery, chemotherapy, radiotherapy, and immunotherapy. However, the prognosis remains poor. This article summarizes the related signaling pathways and factors that may be used as therapeutic targets and early diagnostic biomarkers in the pathogenesis of SCLC. Furthermore, this study provides a theoretical reference for the clinical treatment of SCLC.

Keywords: Small cell lung cancer (SCLC), Signaling pathway, Biomarker, Lung cancer, Chemotherapy, Radiotherapy, Immunotherapy